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Counter statement to open letter to the
Executive Director of the European
Medicines Agency concerning the licensing
of hydroxyethyl starch solutions for fluid
resuscitation
Editor—We were surprised to read the letter of Bellomo and
colleagues1 criticizing the Co-ordination Group for Mutual
Recognition and Decentralised Procedures-human (CMDh)
position related to the benefit/risk evaluation of hydroxy-
lethyl starch (HES)-containing solutions. Since the conclusion
of these EU Article 31 and 107i procedures is based on a
review of all available safety and efficacy data, including
recent data from clinical studies, meta-analyses, post-
marketing experience, and stakeholders’ opinions, it should
be respected.
Notably, the safety signals reported in the three
investigator-initiated trials VISEP, 6S, and CHEST2 – 4 have all
been reported in the setting of critically ill patients in
general and mostly in patients with sepsis. These facts have
been acknowledged and will be included in the product infor-
mation, as proposed by the PRAC and endorsed by the CMDh
by majority vote.
On the contrary, in surgical and trauma patients, the
benefit/risk ratio has been evaluated as positive. This is in line
with the results of many clinical trials and the recent review
article by Van der Linden and colleagues,5 showing, for
example, a decreased requirement of blood transfusion and
no difference in mortality and need for renal replacement
therapy (RRT). These results confirm that the use of modern
HES solutions is safe in the perioperative setting and are con-
gruent with other reports.6 The judgement of a positive
benefit/risk ratio is also in agreement with the majority of sta-
keholders, who have alreadyexpressed theiropinion during the
EU Article 107i procedure.
However, the PRAC has recommended conducting addition-
al clinical studies in the surgical and the trauma setting.
In the letter by Bellomo and associates, it is important to
note that many articles are misquoted like the CRISTAL
study.7 In fact, this clinical trial showed that colloids—when
given in patients with hypovolaemic shock—are life-saving
(significantly reduced 90 day mortality). In this study, 70%
of the patients have been treated with HES. The subgroup ana-
lysis confirmed a significantly reduced 90 day mortality in HES-
treated patients when compared with patients treated with
0.9% saline. Withdrawing HES would therefore not decrease
but increase the risk for patients.
Another example of a misquotation is linked to the refer-
ence James and colleagues,8 which is misleadingly cited to
suggest that HES ‘. . . increases the risk of bleeding and need
for blood products in patients . . . following blunt trauma’.
Notably, the study results do not support the statement of
Bellomo and colleagues. In fact, organ function was better in
penetrating trauma patients treated with 6% HES 130/0.4
when compared with 0.9% saline. Owing to baseline imbal-
ances among groups, no firm conclusion on the treatment
effects in patients with blunt trauma was possible.
In general, Bellomo and colleagues do not differentiate
between HES types with different molecular substitutions and
physicochemical properties. The references cited toreflect nega-
tive effects of HES in part used outdated solutions, for example,
Cittanova and colleagues9 (6% HES 200/0.62), Brunkhorst and
colleagues2 (VISEP-study, 10% HES 200/0.5), and the meta-
analyses including starch solutions of older generations. On
the contrary, there is increasing evidence showing that there
are relevant differences between the effects of the different
products, with the best profile for the latest generation of
starches. This is supported by recent data of the RaFTinG
registry10 that have been evaluated by PRAC in the Article
107i procedure.
In their letter, Bellomo and colleagues did not discuss the
major limitations of the three investigator-initiated studies
VISEP, 6S, and CHEST.2 – 4 In this context, it is important to
note that many patients were already treated before random-
ization and were not hypovolaemic at the time of study inclu-
sion. Accordingly, there was no need of volume therapy in at
least this subset of patients. It is also important to consider
that many patients with contra-indications to HES have been
included in the studies. In addition, dose limitations have
not been respected in the VISEP trial. Overdosing and use
outside the indication of hypovolaemia were associated with
increased mortality. These criticisms have been expressed
by the scientific community.11 Most importantly, data from
the CHEST trial are used incorrectly, although the letter was
written and signed by a number of CHEST investigators: ‘In
CHEST, increased use of renal replacement therapy in intensive
care patients occurred after a total cumulative dose of 5 ml/kg,
one tenth of the maximal dailydose of 50 ml/kg’. This cannot be
correct, since on the first treatment day, a mean dose of 980
ml was administered, which amounts to 12 ml kg21. Moreover,
the cumulative HES dose within the first 4 days of treatment
was 26.5 ml kg21. Thus, the cumulative HES dose was greater
than five times more than acknowledged by Bellomo and
colleagues. It is also important to consider that the difference
in the use of RRT was only of borderline significance between
groups and that no rules for initiating and stopping RRT were
defined.
There are also major concerns about study designs and data
analyses11 in VISEP, 6S, and CHEST. Analyses by independent
third parties are needed to clarify the open issues.
We would also like to express that although some physicians
signed the open letter, it is a minority not taking the current
status of knowledge of the risk–benefit assessment of HES
into account.
In addition, we would like to emphasize that the
conduct of further clinical studies is of high value to gain
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more information on the ‘best treatment’ of surgical and
trauma patients.
Ultimately, it should be in everyone’s interest to interpret the
existing data on medical topics objectively and neutrally,
without rushing to premature, far-reaching conclusions which
could confuse physicians and even render future therapy with
potentially life-saving drugs impossible.
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Evaluation of acoustic respiration rate
monitoring after extubation in intensive
care unit patients
Editor—The Anesthesia Patient Safety Foundation recom-
mends both pulse oximetry (SpO2 ) and respiration rate (RR)
monitoring after extubation1 because in patients receiving
supplemental oxygen, SpO2 alone can be a late indicator of
alveolar hypoventilation.2 We sought to compare the accuracy
of acoustic RR (RRa, Rad-87, software version 7713, MasimoTM
Corp., Irvine, CA, USA) measurement, a relatively new method
of assessment and thoracic impedance RR measurement
(RRi, PhilipsTM Intellivue MP2, Suresnes, France), the widely
used method of assessment, with RR by capnography
(Capno-streamTM 20, Oridion, Jerusalem, Israel) through a
face mask (CapnomaskTM, Mediplus Ltd, Raleigh, NC, USA)3
used as reference method in intensive care unit (ICU) patients
immediately after extubation.
After obtaining informed consent, patients 18 yr or older
were enrolled in the study within 1 h after extubation. Patients
with a neck or facial trauma preventing the application of a
face mask, the acoustic sensor, or both and those requiring
non-invasive ventilation or chest physiotherapy during
recordings were excluded. RR was simultaneously recorded
every second for 30–60 min by the three methods. Adjusted
Bland and Altman analysis was used to calculate bias
and limits of agreement for RRa or RRi compared with
capnography.4
Twenty-five patients [21 men; median (inter-quartile range)
age: 61 (43–64) yr, BMI: 26.2 (23.9–29.6) kg m22, SAPS II
score:5 41 (26–49)] were included. From the 69 347 triplet RR
measurements collected, only 57 520 (83%) were usable due
to removal of values corresponding to periods of calibration
from the capnometer (n¼1034, 1.5%), detachment of RRa
sensor (n¼3643, 5.2%), or the dislodgement of CapnomaskTM
by the patient (n¼7150, 10.3%). Thus, RRa and capnography
accounted for 30.8% and 69.2% of data loss, respectively.
The median RR during recordings as measured by capnography
was 19 (16–25) bpm.
Compared with capnography, bias was similar for acoustic
monitoring and for impedance monitoring, but limits of
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